# US 2025/0152584 A1 · Nlrp3 inflammasome inhibitor and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152584 A1
- Document ID: US20250152584A1
- Status: Published application
- Kind: A1
- Application number: 18/726,248
- Filed: 2023-01-06
- Published: 2025-05-15
- Earliest claimed: 2022-01-07
- Assignees: Transthera Sciences (Nanjing), Inc.
- Applicants: TransThera Sciences (Nanjing), Inc.
- Inventors: Lin Li; Frank Wu
- Web page: https://patentgrep.com/patent/US20250152584A1

## CPC

- A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- C07D 237/20: Nitrogen atoms (nitro radicals C07D237/12)
- C07D 237/26: condensed with carbocyclic rings or ring systems
- C07D 237/34: with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
- C07D 253/07: with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/18: Bridged systems
- C07D 495/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

The present application belongs to the technical field of medicines, relates to an NLRP3 inflammasome inhibitor and the uses thereof, and particularly relates to a compound represented by general formula (A) or a pharmaceutically acceptable salt, a stereoisomer and a tautomer thereof. The inhibitor has biological activity on NLRP3 inflammasome, and has important clinical development value for treatment of NLRP3-related diseases.

## Claims

### Claim 1

A compound of general formula (A) or a pharmacologically acceptable salt, stereoisomer or tautomer thereof:
Y—W—R3 (A)
wherein,
W is selected from
X1 and X2 are each independently selected from C or N;
R1 is selected from hydrogen, hydroxyl, amino, carboxyl, cyano, nitro, halogen, carbonyl, C1-6 alkyl, halo C1-6alkyl, C1-6 alkoxy, halo C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, —N(C1-6 alkyl)2, —S—C1-6 alkyl, or absent;
R2 is selected from hydrogen, hydroxyl, amino, carboxyl, cyano, nitro, halogen, carbonyl, C1-6 alkyl, halo C1-6alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, —N(C1-6 alkyl)2, —S—C1-6 alkyl, or absent;
R1 and R2 are each optionally substituted by 1-3 substituents selected from hydroxyl, amino, carboxyl, cyano, nitro, halogen, carbonyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, and 5-7 membered heteroaryl; or
R1 and R2, together with the carbon or nitrogen atom to which they are attached, form a 5-12 membered ring A, the 5-12 membered ring A is optionally substituted by 1-4 substituents selected from the group consisting of hydroxyl, amino, carboxyl, cyano, nitro, halogen, carbonyl, C1-6 alkyl, —NH—C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, C1-6 alkylsulfonyl, and —N(C1-6 alkyl)2;
R3 is selected from the group consisting of —(C1-6 alkylene)0-2-NR4R5, —(C1-6 alkylene)0-2-NR4—COR5, —(C1-6 alkylene)0-2-CO—NR4—R5, and —(C1-6 alkylene)0-2-NR4—C1-6 alkylene-R5;
R4 is selected from hydrogen or C1-6 alkyl;
R5 is selected from the group consisting of 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, and 5-7 membered heteroaryl; R5 is optionally substituted by 1-4 substituents selected from the group consisting of halogen, cyano, amino, hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, C2-6 alkenylcarbonyl, sulfonyl, and C1-6 alkylcarbonyl;
when R5 is substituted, the substituent on R5, which is C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, or sulfonyl, is optionally substituted by 1-3 substituents selected from the group consisting of halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, 3-6 membered cycloalkyl, 3-6 membered heterocyclyl, carboxyl, and C1-6 alkylsulfonyl;
Y is selected from the group consisting of aryl, 5-14 membered heteroaryl, 3-14 membered heterocyclyl, and 3-12 membered cycloalkyl;
(1) when X1 and X2 are each selected from C,
Y is substituted by C2-6 alkenyl or C2-6 alkynyl, and is optionally substituted by 1-2 substituents selected from the group consisting of halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, C1-6 alkylamino, C1-6 alkylcarbonylamino, C1-6 alkylsulfonyl, aminocarbonyl, C1-6 alkylaminocarbonyl, and sulfonyl;
(2) when either one or two of X1 and X2 is/are selected from N,
Y is optionally substituted by 1-3 substituents selected from the group consisting of C2-6 alkenyl, C2-6 alkynyl, halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, C1-6 alkylamino, C1-6 alkylcarbonylamino, C1-6 alkylsulfonyl, aminocarbonyl, C1-6 alkylaminocarbonyl, sulfonyl, —N(C1-6 alkyl)2, and —S—C1-6 alkyl;
in (1) and (2) above, when Y is substituted,
the substituent on Y, which is C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, or sulfonyl, is optionally substituted by 1-3 substituents selected from the group consisting of halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, and 3-6 membered cycloalkyl; or
the substituent on Y, which is C2-6 alkenyl or C2-6 alkynyl, is optionally substituted by 1-3 substituents selected from the group consisting of halogen, cyano, amino, hydroxy, carbonyl, unsubstituted or hydroxy-substituted C1-6 alkyl, unsubstituted or hydroxy-substituted 3-6 membered cycloalkyl, and C1-6 haloalkyl.

### Claim 2 (depends on 1)

The compound or the pharmaceutically acceptable salt, stereoisomer or tautomer thereof according to claim 1, which has a structure of general formula (I):
wherein,
R1 is selected from the group consisting of hydrogen, hydroxy, amino, carboxyl, cyano, nitro, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, and 5-7 membered heteroaryl;
R2 is selected from the group consisting of hydrogen, hydroxy, amino, carboxyl, cyano, nitro, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, and 5-7 membered heteroaryl;
R1 and R2 are each optionally substituted by 1-3 substituents selected from the group consisting of hydroxy, amino, carboxyl, cyano, nitro, halogen, carbonyl, C1-6 alkyl, haloC1.6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, and 5-7 membered heteroaryl;
or
R1 and R2, together with a carbon atom attached thereto, form a 5-12 membered ring A; the 5-12 membered ring A is optionally substituted by 1-4 substituents selected from the group consisting of hydroxy, amino, carboxyl, cyano, nitro, halogen, carbonyl, C1-6 alkyl, —NH—C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, C1-6 alkylsulfonyl, and —N(C1-6 alkyl)2;
R3 is selected from the group consisting of —(C1-6 alkylene)0-2-NR4R5, —(C1-6 alkylene)0-2-NR4—COR5, —(C1-6 alkylene)0-2-CO—NR4—R5, and —(C1-6 alkylene)0-2-NR4—C1-6 alkylene-R5;
R4 is selected from hydrogen or C1-6 alkyl;
R5 is selected from the group consisting of 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, and 5-7 membered heteroaryl; R5 is optionally substituted by 1-4 substituents selected from the group consisting of halogen, cyano, amino, hydroxy, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, C2-6 alkenylcarbonyl, sulfonyl, and C1-6 alkylcarbonyl;
Y is selected from the group consisting of aryl, 5-14 membered heteroaryl, 3-14 membered heterocyclyl, and 3-12 membered cycloalkyl, and Y is substituted by C2-6 alkenyl or C2-6 alkynyl, and is optionally substituted by 1-2 substituents selected from the group consisting of halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, C1-6 alkylamino, C1-6 alkylcarbonylamino, C1-6 alkylsulfonyl, aminocarbonyl, C1-6 alkylaminocarbonyl, and sulfonyl;
when R5 is substituted, the substituent on R5, which is C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, or sulfonyl, is optionally substituted by 1-3 substituents selected from the group consisting of halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, 3-6 membered cycloalkyl, and C1-6 alkylsulfonyl;
when Y is substituted, the substituent on Y, which is C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, or sulfonyl, is optionally substituted by 1-3 substituents selected from the group consisting of halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, and 3-6 membered cycloalkyl; or
the substituent on Y, which is C2-6 alkenyl or C2-6 alkynyl, is optionally substituted by 1-3 substituents selected from the group consisting of halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, 3-6 membered cycloalkyl, and C1-6 haloalkyl.

### Claim 3 (depends on 2)

The compound of general formula (2) or the pharmaceutically acceptable salt, stereoisomer or tautomer thereof according to claim 2,
wherein,
R1 is selected from the group consisting of hydrogen, hydroxy, amino, carboxyl, cyano, nitro, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, and 5-7 membered heteroaryl;
R2 is selected from the group consisting of hydrogen, hydroxy, amino, carboxyl, cyano, nitro, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, and 5-7 membered heteroaryl;
R1 and R2 are each optionally substituted by 1-3 substituents selected from the group consisting of hydroxy, amino, carboxyl, cyano, nitro, halogen, carbonyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, and 5-7 membered heteroaryl;
or
R1 and R2, together with a carbon atom attached thereto, form a 5-12 membered ring A; the 5-12 membered ring A is optionally substituted by 1-4 substituents selected from the group consisting of hydroxy, amino, carboxyl, cyano, nitro, halogen, carbonyl, C1-6 alkyl, —NH—C1-6 alkyl, haloC1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, C1-6 alkylsulfonyl, and —N(C1-6 alkyl)2;
R3 is selected from the group consisting of —(C1-6 alkylene)0-2-NR4R5, —(C1-6 alkylene)0-2-NR4—COR5, and —(C1-6 alkylene)0-2-CO—NR4—R5;
R4 is selected from hydrogen or C1-6 alkyl;
R5 is selected from the group consisting of 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, and 5-7 membered heteroaryl; R5 is optionally substituted by 1-4 substituents selected from the group consisting of halogen, cyano, amino, hydroxy, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, C2-6 alkenylcarbonyl, sulfonyl, and C1-6 alkylcarbonyl;
Y is selected from the group consisting of aryl, 5-14 membered heteroaryl, 3-14 membered heterocyclyl, and 3-12 membered cycloalkyl, and Y is substituted by C2-6 alkenyl or C2-6 alkynyl, and is optionally substituted by 1-2 substituents selected from the group consisting of halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, C1-6 alkylamino, C1-6 alkylcarbonylamino, C1-6 alkylsulfonyl, aminocarbonyl, C1-6 alkylaminocarbonyl, and sulfonyl;
when R5 is substituted, the substituent on R5, which is C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, or sulfonyl, is optionally substituted by 1-3 substituents selected from the group consisting of halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, and 3-6 membered cycloalkyl;
when Y is substituted, the substituent on Y, which is C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, or sulfonyl, is optionally substituted by 1-3 substituents selected from the group consisting of halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, and 3-6 membered cycloalkyl; or
the substituent on Y, which is C2-6 alkenyl or C2-6 alkynyl, is not substituted.

### Claim 4 (depends on 1)

The compound or the pharmaceutically acceptable salt, stereoisomer or tautomer thereof according to claim 1, which has a structure of general formula (B):
wherein,
R1 is selected from hydrogen, hydroxy, amino, carboxyl, cyano, nitro, halogen, carbonyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, —N(C1-6 alkyl)2, —S—C1-6 alkyl, or absent;
R2 is selected from hydrogen, hydroxy, amino, carboxyl, cyano, nitro, halogen, carbonyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, —N(C1-6 alkyl)2, —S—C1-6 alkyl, or absent;
R1 and R2 are each optionally substituted by 1-3 substituents selected from the group consisting of hydroxy, amino, carboxyl, cyano, nitro, halogen, carbonyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, and 5-7 membered heteroaryl;
either one or two of X1 and X2 is/are selected from N; and
Y is substituted by hydroxy and is optionally substituted by 1-2 substituents selected from the group consisting of C2-6 alkenyl, C2-6 alkynyl, halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, C1-6 alkylamino, C1-6 alkylcarbonylamino, C1-6 alkylsulfonyl, aminocarbonyl, C1-6 alkylaminocarbonyl, sulfonyl, —N(C1-6 alkyl)2, and —S—C1-6 alkyl.

### Claim 5 (depends on 1)

The compound or the pharmaceutically acceptable salt, stereoisomer or tautomer thereof according to claim 1, which has a structure of general formula (II):
wherein,
the ring A is selected from the group consisting of 5-7 membered cycloalkenyl, 5-7 membered cycloalkyl, 5-7 membered heterocyclyl, phenyl, and 5-7 membered heteroaryl; and the ring A is optionally substituted by 1-4 substituents selected from the group consisting of hydroxy, amino, carboxyl, cyano, nitro, halogen, C1-6 alkyl, —NH—C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, aryl, 5-7 membered heteroaryl, C1-6 alkylsulfonyl, and —N(C1-6 alkyl)2.

### Claim 6 (depends on 5)

The compound or the pharmaceutically acceptable salt, stereoisomer or tautomer thereof according to claim 5, wherein,
the ring A is selected from the group consisting of phenyl and 5-7 membered heteroaryl; and the ring A is optionally substituted by 1-4 substituents selected from the group consisting of hydroxy, amino, carboxyl, cyano, nitro, halogen, C1-6 alkyl, —NH—C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, C1-6 alkylsulfonyl, and —N(C1-6 alkyl)2.

### Claim 7 (depends on 1)

The compound or the pharmaceutically acceptable salt, stereoisomer or tautomer thereof according to claim 1, wherein,
Y is selected from the group consisting of phenyl, 5-7 membered heteroaryl, 3-8 membered heterocyclyl, and 3-7 membered cycloalkyl; Y is substituted by C2-6 alkenyl or C2-6 alkynyl, and is optionally substituted by 1-2 substituents selected from the group consisting of halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, C1-6 alkylamino, C1-6 alkylcarbonylamino, C1-6 alkylsulfonyl, aminocarbonyl, C1-6 alkylaminocarbonyl, and sulfonyl; and
when Y is substituted, the substitute on Y, which is C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, or sulfonyl, is optionally substituted by 1-3 substituents selected from the group consisting of halogen, cyano, amino, hydroxy, carbonyl, and C1-6 alkyl.

### Claim 8 (depends on 6)

The compound or the pharmaceutically acceptable salt, stereoisomer or tautomer thereof according to claim 6, wherein,
Y is selected from the group consisting of phenyl, 5-7 membered heteroaryl, 3-8 membered heterocyclyl, and 3-7 membered cycloalkyl; Y is substituted by C2-6 alkenyl, or C2-6 alkynyl, and is optionally substituted by 1-2 substituents selected from the group consisting of halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, C1-6 alkylamino, C1-6 alkylcarbonylamino, C1-6 alkylsulfonyl, aminocarbonyl, C1-6 alkylaminocarbonyl, and sulfonyl;
when Y is substituted, the substituent on Y, which is C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, or sulfonyl, is optionally substituted by 1-3 substituents selected from the group consisting of halogen, cyano, amino, hydroxy, carbonyl, and C1-6 alkyl; and
R3 is selected from —NH—R5, and R5 is 3-7 membered heterocyclyl substituted by 1-2 substituents selected from C1-6 alkyl.

### Claim 9 (depends on 1)

The compound or the pharmaceutically acceptable salt, stereoisomer or tautomer thereof according to claim 1, wherein,
the ring A is selected from the group consisting of 5-12 membered cycloalkyl, 5-12 membered cycloalkenyl, 5-12 membered heterocyclyl, aryl, and 5-12 membered heteroaryl; and preferably, the ring A is selected from the group consisting of 5-8 membered cycloalkyl, 5-8 membered cycloalkenyl, 5-8 membered heterocyclyl, phenyl, and 5-8 membered heteroaryl.

### Claim 10 (depends on 1)

The compound or the pharmaceutically acceptable salt, stereoisomer or tautomer thereof according to claim 1, wherein,
R3 is selected from the group consisting of —NR4R5, and —NR4—C1-6 alkylene-R5, R4 is selected from hydrogen, and R5 is selected from the group consisting of 3-7 membered cycloalkyl, and 3-7 membered heterocyclyl; and preferably, R3 is selected from —NHR5, and R5 is selected from the group consisting of 4-6 membered cycloalkyl and 4-6 membered heterocyclyl.

### Claim 11 (depends on 10)

The compound or the pharmaceutically acceptable salt, stereoisomer or tautomer thereof according to claim 10, wherein,
Y is selected from the group consisting of phenyl and 5-6 membered heteroaryl, and Y is substituted by C2-6 alkenyl or C2-6 alkynyl, and is optionally substituted by 1-2 substituents selected from the group consisting of halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered heterocyclyl, and 3-7 membered cycloalkyl; and C2-6 alkenyl and C2-6 alkynyl are substituted by 1-3 substituents selected from the group consisting of halogen, cyano, amino, hydroxy, carbonyl, C1-6 alkyl, 3-6 membered cycloalkyl, and C1-6 haloalkyl.

### Claim 12 (depends on 5)

The compound or the pharmaceutically acceptable salt, stereoisomer or tautomer thereof according to claim 5, wherein,
the ring A is selected from the group consisting of
and the ring A is optionally substituted by 1-4 substituents selected from the group consisting of hydroxy, amino, carboxyl, cyano, nitro, halogen, C1-6 alkyl, —NH—C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, C1-6 alkylsulfonyl, and —N(C1-6 alkyl)2.

### Claim 13 (depends on 10)

The compound or the pharmaceutically acceptable salt, stereoisomer or tautomer thereof according to claim 10, wherein,
the ring A is selected from the group consisting of
and the ring A is optionally substituted by 1-2 substituents selected from the group consisting of cyano, nitro, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, 3-7 membered cycloalkyl, 5-7 membered heteroaryl, C1-6 alkylsulfonyl, and —N(C1-6 alkyl)2.

### Claim 14 (depends on 4)

The compound or the pharmaceutically acceptable salt, stereoisomer or tautomer thereof according to claim 4, wherein,
Y is selected from the group consisting of

### Claim 15 (depends on 1)

The compound or the pharmaceutically acceptable salt, stereoisomer or tautomer thereof according to claim 1, which is shown as below:

### Claim 16 (depends on 1)

A pharmaceutical composition, comprising the compound or the pharmaceutically acceptable salt, stereoisomer or tautomer thereof according to claim 1, and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 1)

A method for preventing and/or treating NLRP3 inflammasome-related diseases, comprising:
administering the compound or the pharmaceutically acceptable salt, stereoisomer or tautomer thereof according to claim 1 to a subject in need thereof.

### Claim 18 (depends on 1)

A method for preventing and/or treating inflammasome-related diseases, immune diseases, inflammatory diseases, autoimmune diseases, or autoinflammatory diseases, comprising:
administering the compound or the pharmaceutically acceptable salt, stereoisomer or tautomer thereof according to claim 1 to a subject in need thereof.

### Claim 19 (depends on 10)

The compound or the pharmaceutically acceptable salt, stereoisomer or tautomer thereof according to claim 10, wherein,
Y is selected from the group consisting of

### Claim 20 (depends on 16)

A method for preventing and/or treating NLRP3 inflammasome-related diseases or for preventing and/or treating inflammasome-related diseases, immune diseases, inflammatory diseases, autoimmune diseases, or autoinflammatory diseases, comprising:
administering the pharmaceutical composition according to claim 16 to a subject in need thereof.